Supportive Care in Cancer

, Volume 22, Issue 1, pp 7–14 | Cite as

Daptomycin use in neutropenic patients with documented gram-positive infections

  • Kenneth V. I. Rolston
  • Dina Besece
  • Kenneth C. Lamp
  • Min Yoon
  • Scott A. McConnell
  • Pamela White
Original Article



The goal of this study was to describe the outcomes associated with daptomycin treatment of documented gram-positive infections in patients with neutropenia.


All patients with neutropenia (≤500 cells/m3) and at least one documented gram-positive culture from 2006–2009 were identified from a retrospective, multicenter, and observational registry (Cubicin® Outcome Registry and Experience (CORE®)). Investigators assessed patient outcome (cured, improved, failed, nonevaluable) at the end of daptomycin therapy. All patients were included in the safety analysis.


The efficacy population had 186 patients; 159 (85 %) patients had either cure (n = 108, 58 %) or improved (n = 51, 27 %) as an outcome. Success rates (cure plus improved) by the lowest WBC during daptomycin were 98/116 (84 %) for ≤100 cells/m3 and 61/70 (87 %) for 101–499 cells/m3, P = 0.6. Most patients had cancer; 135/186 (73 %) had hematological malignancy; 26/186 (14 %) had solid tumors, and 9 (5 %) had both. One hundred fifty-six (84 %) patients received other antibiotics before daptomycin treatment; 82 % vancomycin, of which 31 % failed vancomycin. The most common infections were bacteremia (78 %), skin and skin structure infections (8 %), and urinary tract infections/pyelonephritis (6 %). The most common pathogens were vancomycin-resistant Enterococcus faecium (47 %), methicillin-resistant Staphylococcus aureus (20 %), and coagulase-negative staphylococci (19 %). The median (min, max) initial daptomycin dose was 6 mg/kg (3.6, 8.3). The median (min, max) daptomycin duration of therapy was 14 days (1, 86). Possibly related adverse events occurred in 12/209 patients (6 %), and 13 patients (6 %) discontinued daptomycin due to adverse event.


The results suggest that daptomycin appeared useful and well tolerated in neutropenic patients, and the degree of neutropenia did not affect daptomycin success rates. Comparative clinical trials are needed to confirm these findings.


Daptomycin Neutropenia Staphylococcus aureus Enterococcus faecium 


  1. 1.
    Bodey GP (1986) Infection in cancer patients. A continuing association. Am J Med 81:11–26PubMedCrossRefGoogle Scholar
  2. 2.
    Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340PubMedCrossRefGoogle Scholar
  3. 3.
    Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56–93PubMedCrossRefGoogle Scholar
  4. 4.
    Rolston KV (2005) Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 40(Suppl 4):S246–S252PubMedCrossRefGoogle Scholar
  5. 5.
    Moellering RC Jr (2006) Vancomycin: a 50-year reassessment. Clin Infect Dis 42(Suppl 1):S3–S4PubMedCrossRefGoogle Scholar
  6. 6.
    Cometta A, Kern WV, de Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Gauser MP, Calandra T, Viscoli C; International Antimicrobial Therapy Group of the European Organization for Research Treatment of Cancer (2003) Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 37(3):382–97Google Scholar
  7. 7.
    Feld R (1999) Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis 29:503–507Google Scholar
  8. 8.
    Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA (1988) Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108:30–35PubMedCrossRefGoogle Scholar
  9. 9.
    Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Rybak MJ, Talan DA, Chambers HF, Infectious Diseases Society of America (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52(3):e18–55PubMedCrossRefGoogle Scholar
  10. 10.
    Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP (2009) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49(3):325–7PubMedCrossRefGoogle Scholar
  11. 11.
    Kapadia M, Coyle E, Prince R, Rolston K (2005) Declining in vitro activity of vancomycin against Staphylococcus aureus isolates from cancer patients. Presented at: 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), December 16–19, 2005, Washington, DC. Abstract No. E-807Google Scholar
  12. 12.
    Mahajan SN, Shah JN, Hachem R, Tverdek F, Adachi JA, Mulanovich V, Rolston KV, Raad II, Chemaly RF (2012) Characteristics and outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist 12(17):1329–1336CrossRefGoogle Scholar
  13. 13.
    Finberg RW, Moellering RC, Tally FP, Craig WA, Pankey GA, Dellinger EP, West MA, Joshi M, Linden PK, Rolston KV, Rotschafer JC, Rybak MJ (2004) The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis 39:1314–1320PubMedCrossRefGoogle Scholar
  14. 14.
    Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD (2007) Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 51:1787–1794PubMedCrossRefGoogle Scholar
  15. 15.
    Steenbergen JN, Alder J, Thorne GM, Tally FP (2005) Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55:283–288PubMedCrossRefGoogle Scholar
  16. 16.
    Barber GR, Lauretta J, Saez R (2007) A febrile neutropenic patient with Enterococcus gallinarum sepsis treated with daptomycin and gentamicin. Pharmacotherapy 27:927–932PubMedCrossRefGoogle Scholar
  17. 17.
    Chaftari AM, Hachem R, Mulanovich V, Chemaly RF, Adachi J, Jacobson K, Jiang Y, Raad I (2010) Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 36:182–186PubMedCrossRefGoogle Scholar
  18. 18.
    Hogan H, Raad I, Rolston K (2007) Daptomycin therapy for gram-positive infections in cancer patients. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and 25th International Congress of Chemotherapy, March 31–April 3, 2007, Munich, Germany. Abstract No. P-1666Google Scholar
  19. 19.
    Hogan HL, Adachi JA, Coyle EA, Rolston KVI (2007) Daptomycin therapy of gram-positive infections (GPI) in pediatric cancer patients. Presented at: 14th International Symposia on Infections in the Immunocompromised Host, June 2007, Thessaloniki, GreeceGoogle Scholar
  20. 20.
    Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR (2007) Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 54:567–571PubMedCrossRefGoogle Scholar
  21. 21.
    Rolston KV, McConnell SA, Brown J, Lamp KC (2010) Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry. Clin Adv Hematol Oncol 8:249–257PubMedGoogle Scholar
  22. 22.
    Rossetti JM, Thatikonda C, Shadduck RK, Sahovic E, Kaplan RB, Kennedy M, Lister J (2008) Daptomycin plus cefepime for moderate and high-risk febrile neutropenic patients with increased risk of gram-positive infection. Biol Blood Marrow Transplantation 14 (supplement):98Google Scholar
  23. 23.
    Rolston KV, Segreti J, Lamp KC, Friedrich LV (2007) Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med 120(Suppl 1):S4–S5PubMedCrossRefGoogle Scholar
  24. 24.
    Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS (1992) Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis 15(Suppl 1):S206–S215PubMedCrossRefGoogle Scholar
  25. 25.
    Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP (1995) Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 39:445–452PubMedCrossRefGoogle Scholar
  26. 26.
    Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP (1996) Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 23:1234–1239PubMedCrossRefGoogle Scholar
  27. 27.
    Erlandson KM, Sun J, Iwen PC, Rupp ME (2008) Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis 46:30–36PubMedCrossRefGoogle Scholar
  28. 28.
    Kraft S, Mackler E, Schlickman P, Welch K, DePestel DD (2011) Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Support Care Cancer 19:1969–1974PubMedCrossRefGoogle Scholar
  29. 29.
    Bio LL, Perez ME, MacDougall C, Gallagher JC (2011) Comparison of linezolid and daptomycin in the treatment of vancomycin-resistant enterococcal bacteremia. Inf Dis Clin Pract 19:343–347CrossRefGoogle Scholar
  30. 30.
    Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R (2009) Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother 53:428–434PubMedCrossRefGoogle Scholar
  31. 31.
    Tran TT, Panesso D, Gao H, Roh JH, Munita JM, Reyes J, Diaz L, Lobos EA, Shamoo Y, Mishra NN, Bayer AS, Murray BE, Weinstock GM, Arias CA (2013) Whole-genome analysis of a daptomycin-susceptible Enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob Agents Chemother 57:261–26832PubMedCrossRefGoogle Scholar
  32. 32.
    Matar MJ, Tarrand J, Raad I, Rolston KV (2006) Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control 34:534–536PubMedCrossRefGoogle Scholar
  33. 33.
    Rolston KV (2008) Review: daptomycin for the treatment of gram-positive infections in neutropenic cancer patients. Clin Adv Hematol Oncol 6:815–817PubMedGoogle Scholar
  34. 34.
    Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD (2011) The relationship between vancomycin through concentrations and nephrotoxicity: a prospective, multi-center trial. Antimicrob Agents Chemother 55:5475–5479PubMedCrossRefGoogle Scholar
  35. 35.
    Lodise TP, Lomaestro B, Graves J, Drusano GL (2008) Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52:1330–1336PubMedCrossRefGoogle Scholar
  36. 36.
    Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, Sherertz R, Hachem R (2007) Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 51:1656–1660PubMedCrossRefGoogle Scholar
  37. 37.
    ZYVOX® (linezolid) (2008) [package insert]. New York, NY: Pharmacia & Upjohn: Division of Pfizer, IncGoogle Scholar
  38. 38.
    Falagas ME, Siempos II, Vardakas KZ (2008) Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 8:53–66PubMedCrossRefGoogle Scholar
  39. 39.
    Narita M, Tsuji BT, Yu VL (2007) Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 27:1189–1197PubMedCrossRefGoogle Scholar
  40. 40.
    Mulanovich VE, Huband MD, McCurdy SP, Lemmon MM, Lescoe M, Jiang Y, Rolston KV, LaSala PR (2010) Emergence of linezolid-resistant coagulase-negative Staphylococcus in a cancer centre linked to increased linezolid utilization. J Antimicrob Chemother 65:2001–2004PubMedCrossRefGoogle Scholar
  41. 41.
    Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–51PubMedGoogle Scholar
  42. 42.
    Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J (2005) Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191:2149–2152PubMedCrossRefGoogle Scholar
  43. 43.
    Rolston KVI, Bodey GP (2006) Infections in patients with cancer. In: Kufe DW, Frei EI, Holland JF et al (eds) Cancer medicine, 7th edn. BC Decker, Inc., Hamilton, Ontario, Canada, pp 2222–2245Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Kenneth V. I. Rolston
    • 1
  • Dina Besece
    • 2
  • Kenneth C. Lamp
    • 2
  • Min Yoon
    • 2
  • Scott A. McConnell
    • 2
  • Pamela White
    • 2
  1. 1.Infectious Diseases, Infection Control and Employee HealthThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Cubist PharmaceuticalsLexingtonUSA

Personalised recommendations